Interesting, I didn’t catch that on my first read and haven’t looked at the clinical trial to see if it has a 1b arm or what protocol is outlined.

It does seem odd not to have the CTC included as that should provide support for accelerated approval as a surrogate endpoint. You may be correct in this is somehow linked to RP. Glad we have another Phase 2 and waiting to see how everything plays out.